Current management of glaucoma

@article{Lusthaus2019CurrentMO,
  title={Current management of glaucoma},
  author={Jed A. Lusthaus and Ivan Goldberg},
  journal={Medical Journal of Australia},
  year={2019},
  volume={210}
}
Glaucoma is an irreversible progressive optic neuropathy, for which the major proven treatment is to lower the intraocular pressure (IOP). Five groups of IOP‐lowering eye drops have varying mechanisms of action. Some drops, such as β‐blockers and α‐2 agonists, have potentially serious systemic side effects. Acetazolamide is the only available oral agent; it is effective at lowering IOP, but significant side effects relegate its use usually to refractory glaucoma. Two new eye drops, netarsudil… 
Advances in the discovery of novel agents for the treatment of glaucoma
TLDR
After more than a decade without new anti-glaucoma drugs, the last year afforded interesting new pharmacological opportunities for the management of this disease.
Conventional glaucoma implants and the new MIGS devices: a comprehensive review of current options and future directions
TLDR
This review will describe each glaucoma drainage device in detail, focusing on their efficacy in reducing IOP and safety profile, and propose potential developments that may help to improve the performance of current devices.
Topical Medication Therapy for Glaucoma and Ocular Hypertension
TLDR
Fixed-combination therapeutics offer greater efficacy, reliable security, clinical compliance, and tolerance than non-fixed combination agents and monotherapy agents, which will become a prefer option for the treatment of glaucoma.
Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies
  • N. Sharif
  • Medicine, Biology
    Frontiers in Pharmacology
  • 2021
TLDR
Since elevated IOP is only one of many risk factors for development of glaucomatous optic neuropathy, a treatise of the role of inflammatory neurodegeneration of the optic nerve and retinal ganglion cells and appropriate neuroprotective strategies to mitigate this disease will be reviewed and discussed.
Intraocular and intracranial pressure in glaucoma patients taking acetazolamide
TLDR
It is suggested that there are periods during the day when the pressure difference across the lamina cribrosa is larger in case of AAZ use, and future studies should focus on improving the noninvasive ICP testing, different doses and dosing schedules ofAAZ, and the time course of IOP in glaucoma patients not taking AAZ.
Treatment of Glaucoma with Natural Products and Their Mechanism of Action: An Update
TLDR
Recent preclinical and clinical studies on various natural products shown to possess neuroprotective properties for retinal ganglion cells, which thereby may be effective in the treatment of glaucoma, are highlighted.
Intraocular pressure-lowering effects of ripasudil, a rho-kinase inhibitor, and selective laser trabeculoplasty as adjuvant therapy in patients with uncontrolled glaucoma
TLDR
Adjuvant SLT or ripasudil in patients with inadequately controlled glaucoma both reduced IOP to a similar degree, but SLT contributed to reducing the number of medications used.
Outcome, influence factor and development of CLS measurement in continuous IOP monitoring: A narrative review.
Changes of Ocular Dimensions as a Marker of Disease Progression in a Murine Model of Pigmentary Glaucoma
TLDR
High-resolution magnetic resonance imaging of the eye area in mice enables reproducible and consistent measures of key dimensions of the eyeball and demonstrates a correlation between some of the ocular dimensions and the IOP of C57Bl/6J mice and DBA/2J mice with moderately advanced glaucomatous pathology.
Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
TLDR
The purpose of this review is to review and summarise the current state of topical CAI prescribing trends, known efficacy and suggested mechanisms and potential influence on ocular haemodynamics for the future of glaucoma management.
...
...

References

SHOWING 1-10 OF 51 REFERENCES
Glaucoma management: relative value and place in therapy of available drug treatments
TLDR
Lowering intraocular pressure (IOP) is the only proven therapeutic intervention for glaucomatous optic neuropathy and medical therapies on the horizon include rho-kinase inhibitors, neuroprotective interventions, and gene therapies.
Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus
  • Q. Nguyen
  • Medicine, Biology
    Patient preference and adherence
  • 2014
TLDR
BBFC had greater IOP-lowering efficacy than brinzolamide or brimonidine monotherapy after 3 months of treatment in patients with open-angle glaucoma or ocular hypertension; thus, BBFC provides an additional fixed-combination therapeutic option for patients who require further efficacious IOP reduction and improved convenience and tolerability versus concomitant administration of two separate medications.
Emerging drugs to treat glaucoma: targeting prostaglandin F and E receptors
TLDR
PGAs activate the prostaglandin F receptor (FP) reducing intraocular pressure (IOP), thereby stabilizing glaucomatous optic neuropathy, and nanotechnological-release delivery of prostaglandsin analogues could lower IOP effectively.
Neuroprotective agents in the management of glaucoma
TLDR
Clinical evidence indicates that lowering intraocular pressure does not prevent progression in all patients; therefore, risk factors other than those related to IOP are involved in the disease, and the need for alternative, non-IOP-lowering treatments focused at preventing progression, that is, neuroprotectants, has become of interest to both the patient and the physician.
XEN Gel Implant: a new surgical approach in glaucoma
TLDR
The studies have shown it to be without any serious adverse events and to have good safety profile encouraging future research on this novel implant, and there is a need to correctly identify selection criteria for patients, who would benefit the most from the XEN Gel Implant.
Collaborative Normal Tension Glaucoma Study
TLDR
As a group, patients with normal tension glaucoma benefit from lowering of IOP, and variable rate of deterioration, as well as lack of progression in a substantial number in 5 years, suggest that treatment should be individualized according to the stage of disease and rate of progression.
Effects of prostaglandin analogues on aqueous humor outflow pathways.
  • Nelson S. Winkler, M. Fautsch
  • Medicine, Biology
    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • 2014
TLDR
The current understanding of prostaglandin analogue biology as it pertains to IOP reduction and improved aqueous humor outflow facility is explored.
...
...